Global Attention Deficit Hyperactivity Disorder (ADHD) Market Growth (Status and Outlook) 2025-2031

Global Attention Deficit Hyperactivity Disorder (ADHD) Market Growth (Status and Outlook) 2025-2031

The global Attention Deficit Hyperactivity Disorder (ADHD) market size is predicted to grow from US$ 13620 million in 2025 to US$ 20380 million in 2031; it is expected to grow at a CAGR of 7.0% from 2025 to 2031.

Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age.

There are two main types of drugs used to treat ADHD: stimulants and non-stimulants

The main manufacturers of stimulants are in Europe and America, and the main manufacturers of non-stimulants are in China.

ADHD is mainly used in hospital pharmacies and retail pharmacies. Among them, in 2020, the market share of retail pharmacies accounted for approximately 83%

Takeda has the highest market share in ADHD by major global companies, which is much higher than the market share of other companies, about 21% in 2020.

LPI (LP Information)' newest research report, the “Attention Deficit Hyperactivity Disorder (ADHD) Industry Forecast” looks at past sales and reviews total world Attention Deficit Hyperactivity Disorder (ADHD) sales in 2024, providing a comprehensive analysis by region and market sector of projected Attention Deficit Hyperactivity Disorder (ADHD) sales for 2025 through 2031. With Attention Deficit Hyperactivity Disorder (ADHD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Attention Deficit Hyperactivity Disorder (ADHD) industry.

This Insight Report provides a comprehensive analysis of the global Attention Deficit Hyperactivity Disorder (ADHD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Attention Deficit Hyperactivity Disorder (ADHD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Attention Deficit Hyperactivity Disorder (ADHD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Attention Deficit Hyperactivity Disorder (ADHD) and breaks down the forecast by Type, by Distribution Channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Attention Deficit Hyperactivity Disorder (ADHD).

This report presents a comprehensive overview, market shares, and growth opportunities of Attention Deficit Hyperactivity Disorder (ADHD) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Stimulant
Non-stimulant

Segmentation by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
CTFH

Please note: The report will take approximately 2 business days to prepare and deliver.